DE69729209T2 - Humanisierte anti-koerper gegen cd11a - Google Patents

Humanisierte anti-koerper gegen cd11a Download PDF

Info

Publication number
DE69729209T2
DE69729209T2 DE69729209T DE69729209T DE69729209T2 DE 69729209 T2 DE69729209 T2 DE 69729209T2 DE 69729209 T DE69729209 T DE 69729209T DE 69729209 T DE69729209 T DE 69729209T DE 69729209 T2 DE69729209 T2 DE 69729209T2
Authority
DE
Germany
Prior art keywords
antibody
cd11a
humanized
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69729209T
Other languages
German (de)
English (en)
Other versions
DE69729209D1 (de
DE122004000047I2 (de
Inventor
M. Paula JARDIEU
G. Leonard PRESTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69729209D1 publication Critical patent/DE69729209D1/de
Application granted granted Critical
Publication of DE69729209T2 publication Critical patent/DE69729209T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69729209T 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a Expired - Lifetime DE69729209T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
US757205 1996-11-27
PCT/US1997/019041 WO1998023761A1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Publications (2)

Publication Number Publication Date
DE69729209D1 DE69729209D1 (de) 2004-06-24
DE69729209T2 true DE69729209T2 (de) 2005-05-19

Family

ID=25046834

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69729209T Expired - Lifetime DE69729209T2 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a
DE1997629209 Active DE122004000047I2 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen CD11A
DE200412000047 Pending DE122004000047I1 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE1997629209 Active DE122004000047I2 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen CD11A
DE200412000047 Pending DE122004000047I1 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a.

Country Status (17)

Country Link
EP (2) EP1516629B1 (Direct)
JP (2) JP3778945B2 (Direct)
KR (1) KR100532178B1 (Direct)
AR (1) AR008919A1 (Direct)
AT (1) ATE267257T1 (Direct)
AU (1) AU731817C (Direct)
CA (1) CA2272842C (Direct)
DE (3) DE69729209T2 (Direct)
DK (2) DK1516629T3 (Direct)
ES (1) ES2221045T3 (Direct)
FR (1) FR04C0028I2 (Direct)
IL (3) IL130143A0 (Direct)
LU (1) LU91122I2 (Direct)
NL (1) NL300163I2 (Direct)
PT (1) PT941344E (Direct)
WO (1) WO1998023761A1 (Direct)
ZA (1) ZA979599B (Direct)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
US6652855B1 (en) * 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
WO2001043773A1 (en) * 1999-12-14 2001-06-21 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
CA2417432C (en) * 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
ES2357505T3 (es) 2002-09-11 2011-04-27 Genentech, Inc. Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
MXPA05011406A (es) * 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
EP1761562B1 (en) 2004-02-19 2013-09-11 Dyax Corp. Conformation specific antibodies
BRPI0511305A (pt) * 2004-06-09 2007-12-04 Genentech Inc método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
MX2009007632A (es) 2007-01-22 2009-07-24 Genentech Inc Precipitacion de polielectrolito y purificacion de proteinas.
CN112480255B (zh) 2007-07-09 2024-09-27 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
SI2279412T1 (sl) * 2008-04-09 2017-10-30 Genentech, Inc., Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
JP5705115B2 (ja) 2008-09-10 2015-04-22 ジェネンテック， インコーポレイテッド 蛋白質の酸化的分解の予防のための組成物および方法
EP2370561B1 (en) 2008-12-16 2019-08-07 EMD Millipore Corporation Stirred tank reactor and method
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
CA2752884A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
ES2793348T5 (en) 2009-08-11 2025-04-11 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
KR101764449B1 (ko) 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
WO2011060135A1 (en) 2009-11-12 2011-05-19 Vbi Technologies, Llc Subpopulations of spore-like cells and uses thereof
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
KR101551295B1 (ko) 2010-05-17 2015-09-08 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
JP5894154B2 (ja) 2010-06-24 2016-03-23 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化のためのアルキルグリコシドを含む組成物及び方法
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2013096322A1 (en) 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
JP6225162B2 (ja) 2012-03-27 2017-11-01 ジェネンテック， インコーポレイテッド 組換えタンパク質の改良された収集操作
KR102201607B1 (ko) 2012-05-18 2021-01-12 제넨테크, 인크. 고농도 모노클로날 항체 제제
US9393327B2 (en) 2012-12-19 2016-07-19 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
EP3019240B1 (en) 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
JP6636920B2 (ja) 2013-07-16 2020-01-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
AU2015287760B2 (en) 2014-07-09 2019-06-20 Genentech, Inc. pH adjustment to improve thaw recovery of cell banks
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
KR102279524B1 (ko) 2015-09-25 2021-07-20 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
CN115260310B (zh) 2015-11-24 2025-02-25 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
CN109312299A (zh) 2016-03-29 2019-02-05 格尔托公司 蛋白质在具有0.5:1至10:1的周质体积与细胞质体积比的革兰氏阴性菌中的表达
EP3558366A1 (en) 2016-12-22 2019-10-30 H. Hoffnabb-La Roche Ag Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
CN112839954A (zh) 2018-07-03 2021-05-25 百时美施贵宝公司 生产重组蛋白的方法
MA53859A (fr) 2018-10-10 2022-01-19 Boehringer Ingelheim Int Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
JP7777451B2 (ja) 2019-04-12 2025-11-28 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
JP2022543781A (ja) 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
AU731817B2 (en) 2001-04-05
IL130143A (en) 2006-08-01
EP0941344B1 (en) 2004-05-19
ATE267257T1 (de) 2004-06-15
EP1516629A2 (en) 2005-03-23
KR100532178B1 (ko) 2005-12-01
EP0941344A1 (en) 1999-09-15
NL300163I1 (nl) 2005-01-03
DE122004000047I1 (de) 2005-04-21
JP2006036779A (ja) 2006-02-09
KR20000069147A (ko) 2000-11-25
AR008919A1 (es) 2000-02-23
JP3778945B2 (ja) 2006-05-24
FR04C0028I2 (Direct) 2007-10-26
JP2001505425A (ja) 2001-04-24
WO1998023761A1 (en) 1998-06-04
IL130143A0 (en) 2000-06-01
LU91122I2 (fr) 2005-01-10
AU4992997A (en) 1998-06-22
EP1516629B1 (en) 2013-04-03
AU731817C (en) 2001-11-01
PT941344E (pt) 2004-10-29
CA2272842C (en) 2012-05-15
DE69729209D1 (de) 2004-06-24
NL300163I2 (nl) 2005-07-01
DE122004000047I2 (de) 2006-06-14
ES2221045T3 (es) 2004-12-16
EP1516629A3 (en) 2006-09-27
DK0941344T3 (da) 2004-09-27
ZA979599B (en) 1999-04-28
JP4309383B2 (ja) 2009-08-05
DK1516629T3 (da) 2013-06-03
CA2272842A1 (en) 1998-06-04
IL175583A0 (en) 2006-09-05
FR04C0028I1 (Direct) 2005-02-11

Similar Documents

Publication Publication Date Title
DE69729209T2 (de) Humanisierte anti-koerper gegen cd11a
US6703018B2 (en) Method of treatment using humanized anti-CD11a antibodies
DE69819332T2 (de) VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN
DE69938054T2 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
DE69637408T2 (de) Antikörper gegen cd-80
DE69836729T2 (de) Anti-vefg antibodies
US5869619A (en) Modified antibody variable domains
DE69735596T3 (de) Humanisiertes immunglobulin gegen den alpha4beta7-integrin
DE69934515T2 (de) Humanisierte monoklonale inetegrin antikörper
US5770196A (en) Modified antibody variable domains and therapeutic uses thereof
DE69232944T2 (de) Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
DE69233192T2 (de) Humanisierter antikörper gegen cd18
KR20100113589A (ko) 폰 빌레브란트 인자에 특이적인 인간화 항체
JP2004000249A (ja) 抗体の調製
DE69828154T2 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69428272T2 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
US8017115B2 (en) Therapeutical use of anti-myelin associated glycoprotein (MAG) antibodies
US20040146507A1 (en) Antibody mutants
EP0946727B1 (en) Antibody mutants
MXPA99004795A (en) HUMANIZED ANTI-CD11a ANTIBODIES
US20030229207A1 (en) Modified antibody variable domains
MXPA99007688A (en) Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics

Legal Events

Date Code Title Description
R071 Expiry of right